WANA (Sep 20) – For the first time in Iran, a specialized drug has been developed to control and slow the progression of pulmonary fibrosis, helping patients breathe more easily by reducing lung inflammation.
Pulmonary diseases such as fibrosis have long required specialized and effective treatments. Now, domestic innovators have made a significant step in improving patients’ quality of life by producing an advanced Iranian medication.
A knowledge-based company has successfully developed a drug that slows the progression of progressive lung diseases. By reducing inflammation and fibrosis in lung tissue, the drug significantly improves respiratory function.
Maryam Navabakhsh from the company’s pharmaceutical unit explained in an interview that the product, nintedanib, marketed under the brand name Ofenit, is a specialized treatment for patients with pulmonary fibrosis—previously, no Iranian-made drug existed for this condition.
Navabakhsh added that while the foreign equivalent costs around $1,000, the domestically produced version is priced at roughly one-tenth of that, making it accessible to patients and offering hope for better treatment and quality of life. She emphasized that the drug is produced with high-quality raw materials and meets strict quality standards.
She further stated that the medication has shown effectiveness in improving lung function for patients and will be officially launched in the market within approximately ten days.
The developer highlighted the urgent need for this product, noting that for some types of pulmonary fibrosis in Iran, no treatment previously existed.
This knowledge-based product was unveiled at the 23rd Annual Conference of Pardis Technology Park in the International Innovation Zone of Iran.
Iran Launches First Domestic Drug for Pulmonary Fibrosis. Social media/ WANA News Agency